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The detergent sodium dodecyl sulfate is a well-
known inducer of irritant contact dermatitis. In this
study we show that sodium dodecyl sulfate induces
the serine proteinase inhibitor, plasminogen activator
inhibitor type 2, in epidermal keratinocytes. The
enhancement in plasminogen activator inhibitor type
2 mRNA and antigen is observed both when sodium
dodecyl sulfate is applied topically to normal human
skin as well as when it is added to the growth
medium of cultured human keratinocytes. In vitro,
plasminogen activator inhibitor type 2 mRNA is
increased within 4±8 h after addition of the deter-
gent, and the increase in plasminogen activator inhi-
bitor type 2 antigen occurs slightly later. The
enhancing effect of sodium dodecyl sulfate on plas-
minogen activator inhibitor type 2 is not related to
nonspeci®c cell lysis nor is it secondary to induction
of tumor necrosis factor a. Similarities between our
in vitro and in vivo ®ndings lead us to hypothesize
that sodium dodecyl sulfate may exert its effect on
epidermal plasminogen activator inhibitor type 2 via
interaction with the keratinocyte. J Invest Dermatol
117:647±653, 2001
P
lasminogen activator inhibitor type 2 (PAI-2) is an
unusual serine proteinase inhibitor (serpin) that is
synthesized in high amounts in normal strati®ed
squamous epithelia, including epidermis and oral
epithelium (Hibino et al, 1988; Remold-O'Donnell,
1993; Lyons-Giordano et al, 1994; Kruithof et al, 1995; Risse et al,
1998, 2000, Kinnby et al, 1999). PAI-2 is not ef®ciently secreted, as
it lacks a consensus signal sequence, and thus it accumulates inside
the keratinocyte and other cells (Belin et al, 1989; Wang and
Jensen, 1998). The intracellular localization of PAI-2 seems
inconsistent with the fact that the known target proteinases for
PAI-2 (i.e., urokinase and tissue type plasminogen activators) are
both secreted enzymes. The discrepancy in localization between
inhibitor and expected targets has led to speculation about the
possible existence of one or more alternative, intracellular target
proteinases, inhibition of which could constitute an intracellular
function for PAI-2 in strati®ed squamous epithelia (Risse et al,
2000). Alternatively, it cannot be ruled out that PAI-2 may play
some kind of structural role, independent of its proteinase
inhibitory activity.
Several lines of evidence have suggested that PAI-2 may have a
role in normal epidermal differentiation. (i) In normal human and
neonatal mouse epidermis, PAI-2 is synthesized predominantly in
the super®cial, i.e., more differentiated, layers (Lyons-Giordano
et al, 1994; Risse et al, 1998, 2000). (ii) PAI-2 antigen is
concentrated around the periphery of keratinocytes in the granular
layer (i.e., the most differentiated viable layer) of human epidermis.
This localization is similar to the distribution of transglutaminase 1,
which is the enzyme responsible for cross-linking proteins into the
corni®ed envelope, the end product of keratinocyte terminal
differentiation (Thacher and Rice, 1985; Lyons-Giordano et al,
1994; Risse et al, 2000). (iii) PAI-2 is a substrate for transglutami-
nase and is incorporated into the corni®ed envelope of cultured
human keratinocytes (Jensen et al, 1994, 1995; Robinson et al,
1997).
There is also evidence that PAI-2 expression is modulated during
cutaneous wound repair. Epidermal PAI-2 mRNA is rapidly
increased upon perturbation of normal mouse skin, e.g., by gentle
plucking of hairs or by removing the stratum corneum with sticky
tape (Jensen and Lavker, 1996). High levels of PAI-2 mRNA and
antigen have been reported in keratinocytes that are expanding to
cover an epidermal defect in human patients (Bechtel et al, 1998).
Consistent with these in vivo data, PAI-2 is expressed in all
keratinocytes of early stage organotypic cultures, which resemble
epithelia in the process of repair; however, PAI-2 expression is
limited to the suprabasal keratinocyte layers when the cultures
become highly strati®ed and differentiated, much like its expression
pattern in normal epidermis (Chen et al, 1993; Bechtel et al, 1998).
Finally, PAI-2 is strongly increased upon incubation of keratinocyte
cultures with tumor necrosis factor a (TNF-a), a proin¯ammatory
stimulus (Wang and Jensen, 1998).
To address further the regulation of PAI-2 during epidermal
disruption, we have turned to a well-established model of irritant
contact dermatitis, i.e., topical application of sodium dodecyl sulfate
(SDS). Although quantitatively the responses of individual volun-
teers to SDS treatment are quite variable, several hallmark clinical
effects are notable: disrupted barrier function, as measured by
increased transepidermal water loss; erythema; increased epidermal
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thickness; and recruitment of in¯ammatory cells (Willis et al, 1993;
Lee and Maibach, 1995). Several mechanisms have been proposed
for the cutaneous effects of SDS, including disruption of the
stratum corneum lipid sheets, denaturation of proteins, and direct
effects on keratinocytes (Elias, 1996; Fartasch et al, 1998; Welzel
et al, 1998). Evaluating the potential mechanisms of SDS action in
an in vivo setting is fraught with dif®culty, leading to attempts to
develop simpler models. In keratinocyte cultures, which do not
form a functional barrier and do not have any in¯ammatory cell
component, SDS is able to elicit some of the effects observed upon
topical application in vivo (van Ruissen et al, 1998). These ®ndings
argue strongly that some of the effects of SDS on epidermis are
mediated through direct effects on the keratinocytes. In this study,
we have evaluated the effect of SDS on PAI-2 expression in normal
volunteers and in human keratinocyte cultures.
MATERIALS AND METHODS
SDS treatment of human skin An occlusion patch saturated with 1%
(35 mM) SDS was applied for 24 h to the lower back of six volunteers,
followed by 3 mm punch biopsies (of three subjects) or shave biopsies
(of three subjects) from the treated skin. Control skin that had been
under an occlusion patch without SDS for the same period of time was
biopsied concurrently from the same volunteers. For all subjects, biopsies
were embedded in OCT compound (TissueTek; Sakura Finetek USA,
Terrance, CA) with liquid nitrogen, and the tissue was sectioned at
5 mm for immunohistochemistry. For three of the subjects, each biopsy
was divided in half, with one half embedded as above and the other half
®xed for 24 h in 4% paraformaldehyde, processed for paraf®n sections,
and utilized for in situ hybridization.
Calculation of epidermal SDS concentration following patch
application We utilized the values in two published studies in which
the amount of SDS in the epidermis was assayed after topical application
of 1% SDS under occlusion for 24 h. Speci®cally, in hairless rat skin, a
concentration of 6.3 mmol SDS per gram of tissue was measured in the
epidermis under the treatment patch (Patil et al, 1995). If we assume that
a gram of tissue is equivalent to 1 ml of water, then we can estimate that
the average concentration of SDS in the epidermis was 6.3 mM (1.8 mg
per ml). In another study, when 60 ml of 1% SDS was applied under
occlusion for 24 h to human cadaver skin, an average of 32% of the
applied dose of SDS was recovered in the epidermis under the 1.8 cm2
treatment patch (Fullerton et al, 1994). To estimate the concentration of
SDS in the epidermis in this study, we have assumed that the thickness
of human epidermis is 46 mm (Nickoloff and Naidu, 1993), which
allows us to estimate the volume of epidermal tissue in which SDS was
recovered (i.e., 8 ml). Using these estimates, we calculate that the
concentration of SDS in the epidermis was approximately 24 mg per ml
(83 mM).
In situ hybridization In situ hybridization was carried out as described
previously, using 35S-labeled antisense or sense cRNA probes transcribed
from a 463 bp PstI/XbaI fragment, spanning nucleotides 327±790 of
human PAI-2 cDNA (Lyons-Giordano et al, 1994; Risse et al, 2000).
Immunohistochemistry Frozen sections were ®xed in acetone at
±20°C for 10 min; washed in phosphate-buffered saline (PBS);
preincubated in 10% normal horse serum in PBS for 30 min; and
incubated 60 min at room temperature with primary antibody diluted to
3 mg per ml in 10% normal horse serum in PBS, as described previously
(Risse et al, 2000). Primary antibodies were mouse antihuman PAI-2 IgG
(#3750; American Diagnostica, Greenwich, CT) or, as a control, normal
mouse IgG. After washing with PBS, the sections were incubated for
60 min at room temperature with horse antimouse biotinylated antibody
(Vector Laboratories, Burlingame, CA) diluted 1:200 in 10% normal
horse serum/PBS. After again washing with PBS, the sections were
incubated for 45 min with ABC reagent (Elite Vectastain kit, Vector
Laboratories), prepared as recommended by the manufacturer. The stain
was visualized by incubation with 3,3¢-diaminobenzidine (DAB)
solution; a 10 mg tablet (#5905, Sigma Chemical, St. Louis, MO) was
dissolved in 15 ml 0.1 M Tris-HCl pH 7.6 with 120 ml of 3% H2O2.
Incubation times with DAB ranged from 3 to 7 min. Slides were
dehydrated and mounted in Permount (Fisher Chemicals, Fair Lawn,
NJ).
Keratinocyte cultures Keratinocyte cultures were initiated from
neonatal foreskin and propagated in serum-free MCDB medium with
low (i.e., 30 mM) Ca2+ and additives, as previously described (Ando and
Jensen, 1996). For experiments, second or third passage keratinocytes
were seeded into six-well culture dishes and grown until approximately
60%±70% con¯uent. At this time, bovine pituitary extract (BPE) was
omitted from the culture medium and incubation was continued until
the cultures became con¯uent, which usually took 48 h. BPE was
omitted from the culture medium at subcon¯uence and through the rest
of the experiment because preliminary experiments showed that this
additive had an enhancing effect on PAI-2 expression. In most
experiments, except as noted, when the cultures reached con¯uence, the
concentration of Ca2+ in the medium was elevated to 1.0 mM in order
to induce strati®cation and differentiation. After 48 h in medium with
elevated Ca2+, the keratinocytes were treated with SDS (ultraPURE,
99.5% purity, GibcoBRL, Grand Island, NY) at concentrations ranging
from 3.0 to 25.0 mg per ml (10±87 mM) for 2±24 h. These
concentrations are well below the critical micelle concentration for SDS,
which is approximately 1 mM in physiologic saline (Tanford, 1980).
RNase protection Total cellular RNA from keratinocyte cultures was
extracted using the Purescript RNA Isolation Kit (Gentra Systems,
Minneapolis, MN). PAI-2 mRNA was quanti®ed by RNase protection,
using the Ambion RPA III RNase Protection Assay kit (Ambion,
Austin, TX). Biotinylated antisense riboprobes were prepared from the
463 bp Pst I/Xba I fragment of human PAI-2 cDNA described above
under in situ hybridization, and from a 103 bp fragment of human
cyclophilin, spanning nucleotides 38±140 (Ambion). Total cellular RNA
(3.5 mg) was hybridized with 150 pg of biotinylated probe overnight at
42°C. Unhybridized RNA was digested with RNAse T1 (5000 units per
ml). Protected RNA fragments were precipitated and resolved by gel
electrophoresis using 5% polyacrylamide with 8 M urea, followed by
electroblot transfer to nylon membrane (Roche Molecular Biochemicals,
Indianapolis, IN). After ultraviolet crosslinking of the membranes,
protected mRNA was detected with the Brightstar Bio Detect Kit
(Ambion) using streptavidin-alkaline phosphatase and CDP-Star
chemiluminescence.
Immunoblot Cell-associated protein was extracted by scraping
keratinocyte cultures into 0.1 M Tris-HCl pH 8.1 with 0.2% Triton X-
100 (Tris/Triton buffer; 200 ml per 9.5 cm2 well). In several control
experiments, the remaining pellet after Tris/Triton extraction was
subjected to a more rigorous extraction in 25 mM Tris-HCl, pH 7.6,
1 mM MgCl2, 1 mM ethyleneglycol-bis(b-aminoethyl ether)-
N,N,N¢,N¢-tetraacetic acid, 1% Triton X-100, and 1% SDS. Cellular
debris was removed by centrifugation at 16,000g, and samples were
stored at ±70°C. Total protein concentrations were determined using
Pierce BCA Protein Assay Reagents (Pierce, Rockford, IL). Samples
containing 1 mg of total protein were resolved by 9.5% denaturing
polyacrylamide gel electrophoresis and then transferred to nitrocellulose
membrane. Immunoblotting was performed with mouse antihuman PAI-
2 IgG (#3750; American Diagnostica) diluted to 5 mg per ml or with
rabbit antihuman involucrin antibody (BT601; Biomedical Technologies,
Stoughton, MA), diluted 1:100 in 5% dry milk in Tris-buffered saline
(20 mM Tris-HCl pH 7.6, 0.137 M NaCl) containing 0.2% Tween 20
(Sigma). Bands were visualized using horseradish peroxidase linked sheep
antimouse IgG and ECL (both from Amersham Pharmacia Biotech,
Piscataway, NJ). We consistently observed a 41 kDa band in the Tris/
Triton extracts, consistent with the nonglycosylated form of PAI-2. No
additional PAI-2 was extracted by subsequent treatment with SDS-
containing buffer. No detectable corni®ed envelopes were formed under
the culture conditions utilized in this study, so PAI-2 accumulation in
such structures (Jensen et al, 1995) cannot complicate interpretation of
the results.
Quanti®cation of non-speci®c cell lysis To consider the possibility
of nonspeci®c cell lysis induced by treatment of keratinocyte cultures
with SDS, the release of lactate dehydrogenase (LDH) from cells was
quanti®ed. Conditioned media from control and SDS-treated cultures
were assayed using the Promega CytoTox96 Non-Radioactive
Cytotoxicity Assay kit (#G1780; Promega, Madison, WI), following the
manufacturer's protocol. Conditioned media from keratinocyte cultures
incubated without and with SDS at varying concentrations were mixed
with freshly reconstituted substrate mix (50 ml each) and incubated in the
dark for 30 min at room temperature. The enzymatic reaction was
terminated by addition of 50 ml per sample of stop solution, and
absorbance at 490 nm was recorded using a microtiter plate reader.
Control keratinocyte wells were lyzed by repeated freeze±thaw; serial
dilutions of this lysate were included in the assay to determine the
maximal LDH release. Background readings were determined using
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culture medium that had never been incubated with cells. Cytotoxicity
in a given sample was calculated using the following formula:
% cytotoxicity =
[(Abs[490 nm] cells ± Abs[490 nm]medium control) 4
(Abs[490 nm]maximal release control ± Abs[490 nm]medium control)] 3 100
TNF-a enzyme-linked immunosorbent assay (ELISA) and
treatment of cultures with anti-TNF-a antibody A human TNF-
a ELISA kit was purchased (DuoSet #DY210; R&D Systems,
Minneapolis, MN). The assay was carried out as described by the
manufacturer except that peroxidase substrate was purchased from
Kirkegaard & Perry (1 component TMB microwell #50±76±18;
Gaithersburg, MD). Because the levels of SDS added to the culture
media interfered with the assay, conditioned media were dialyzed
overnight against PBS prior to ELISA.
In one group of experiments, keratinocyte cultures were treated with
SDS in the presence of 10 mg per ml of a neutralizing monoclonal
antibody to TNF-a (catalog #MAB210; R&D Systems).
RESULTS
SDS induces PAI-2 in epidermis in vivo To evaluate the effect
of SDS on PAI-2 expression in vivo, SDS was applied under
occlusion for 24 h to six normal human volunteers. Histologic
examination of the SDS-treated skin consistently revealed
compaction of the stratum corneum, with variable dissociation of
the upper corni®ed layers, leaving a thin, dense layer of
corneocytes. In all subjects, we observed a mild in¯ammatory
in®ltrate, consisting mostly of mononuclear cells, localized just
beneath the basement membrane and occasionally within the
epidermis. In four of six subjects, the epidermis showed thickening
with varying degrees of spongiosis, mostly within the stratum
spinosum. These same four subjects also demonstrated some
acantholysis, in one case displaying signs of beginning
dyskeratosis. These observations, including the variability among
normal subjects with regard to extent of response to SDS, are
consistent with previous reports (Lee and Maibach, 1995).
To evaluate the effect of SDS on PAI-2 expression in vivo,
immunohistochemical staining and in situ hybridization were
carried out on control and SDS-treated biopsies from the same
individuals. As we have previously shown, in normal, control
human epidermis, PAI-2 antigen was predominantly localized in
the granular layer, where it was concentrated along the periphery of
the cells (Fig 1A). In SDS-treated skin from four of six subjects, we
detected an increase in the number of epidermal layers exhibiting
PAI-2 staining, with positive cells extending well into the spinous
layers (Fig 1B, C), which in control skin did not contain detectable
Figure 2. Expression of epidermal PAI-2
mRNA was induced after SDS treatment of
normal human skin. Paraf®n sections of normal
human skin from donor #2, untreated (A, C) or
SDS treated (B, D), were processed for in situ
hybridization using antisense or sense riboprobes
to PAI-2. Scale bar: 100 mm.
Figure 1. Expression of epidermal PAI-2
antigen was induced after SDS treatment of
normal human skin. Frozen sections of normal
human skin untreated (A) or SDS treated (B±D)
were processed for immunohistochemical staining
with anti-PAI-2 monoclonal antibody #3750 (A±
C) or with normal mouse IgG (D). Dotted lines
indicate the dermal±epidermal junction. Parts (A)
and (B) were derived from donor #1, and parts
(C) and (D) were from donor #2. Scale
bar: 100 mm. Note that the brownish color in part
(D) is mostly due to melanin.
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PAI-2 antigen. In two of six cases this extension of PAI-2 staining
was observed in most ®elds throughout the biopsy (Fig 1B);
however, in the two other cases, the increase in PAI-2 staining was
limited to focal areas within the epidermis (Fig 1C). Regions of
most extensive PAI-2 staining were present in the biopsies with the
most obvious histologic changes. Two subjects showed no effect of
SDS on the staining pattern for PAI-2.
In situ hybridization for PAI-2 mRNA was performed with
biopsies from three subjects. In untreated skin, the signal for PAI-2
mRNA was uniformly weak but concentrated in the granular layer,
as observed previously (Risse et al, 2000; Fig 2A). In the subject
whose epidermis showed the greatest SDS response histologically,
PAI-2 mRNA signal was dramatically increased (Fig 2B). The
strongest increase of PAI-2 mRNA was found in the keratinocytes
adjacent to epidermal regions with clear signs of epidermal
disruption, e.g. spongiosis and acantholysis. More modest increases
were detected in other ®elds throughout the biopsy, with signal
generally concentrated in the spinous and basal layers. The other
two subjects showed weaker PAI-2 mRNA induction after SDS,
with only focal regions of increased PAI-2 mRNA signal compared
to control biopsies. Thus, topical treatment with SDS for 24 h
induced focal increases of PAI-2 mRNA in the basal and spinous
layers and of PAI-2 antigen in the spinous layers. The fact that we
do not detect increased PAI-2 antigen in the basal layer, in spite of
PAI-2 mRNA increases, may indicate some post-transcriptional
inhibitory regulation speci®c to the basal cells.
SDS induces PAI-2 in cultured keratinocytes In most of the
following studies to determine the effect of SDS on keratinocyte
PAI-2 in vitro, we used a culture model that was strati®ed and
differentiated. Keratinocyte cultures were grown to con¯uence;
then the Ca2+ concentration in the medium was elevated to
1.0 mM for two more days of incubation, in order to generate
cultures containing four to six cell layers expressing numerous
differentiation markers (Jensen et al, 1997).
Initially, SDS was tested at concentrations ranging from 3 to
25 mg per ml (10±87 mM) for incubations of 16 h (for RNase
protection) or 24 h (for immunoblot). SDS at 3 mg per ml led to an
increase in PAI-2 mRNA (Fig 3A); a further increase in PAI-2
mRNA was observed at 6 mg per ml SDS, which represented a
plateau value maintained up to 10±12.5 mg per ml SDS, depending
upon the culture. Little to no effect of SDS was detectable on
cyclophilin mRNA, which was included as a control. SDS also
induced a concentration-dependent increase in PAI-2 antigen. The
maximal increase was observed at 6±8 mg per ml SDS, with a
diminished effect in most cultures at 12.5 mg per ml (Fig 3B). By
25 mg per ml SDS, PAI-2 mRNA and protein sharply declined,
concordant with lysis of the cells (see below). In most experiments
there was no effect on the differentiation marker involucrin at SDS
concentrations from 3 to 25 mg per ml, although some cultures
showed a modest increase.
Time courses of the effects on PAI-2 mRNA and protein were
determined using 8 mg per ml SDS, which was shown in Fig 3 to
be an optimal concentration. In some cultures, after 4 h of
incubation there was a small increase in the level of PAI-2 mRNA;
however, by 8 h of incubation, there was a consistent dramatic
Figure 3. SDS-mediated induction of PAI-2 in cultured
keratinocytes was concentration dependent. Human keratinocytes
were incubated in the absence or presence of SDS at 3±12.5 mg per ml.
After 16 h of incubation, total RNA was extracted for RNase protection
assay of PAI-2 mRNA and, as a reference control, cyclophilin mRNA
(A). In parallel experiments, after 24 h of incubation, cell-associated
protein was recovered for Western blotting using antibodies to PAI-2
and involucrin (B).
Figure 4. SDS-mediated induction of PAI-2 in cultured
keratinocytes was time dependent. Human keratinocytes were
incubated with 8 mg per ml SDS for 2±24 h. Total RNA or cell-
associated protein were extracted and assayed by RNase protection assay
(A) or Western blotting (B), as described in Fig 3. Controls were
cyclophilin and involucrin for RNase protection and Western blotting,
respectively.
Figure 5. SDS treatment of cultured keratinocytes induced
concentration-dependent changes in cellular morphology. Normal
human keratinocytes were grown to con¯uence in low Ca2+ MCDB
medium; Ca2+ was then elevated to 1.0 mM to induce strati®cation and
differentiation. After 2 d of incubation, SDS was added at 6 mg per ml
(B) or 12.5 mg per ml (C); a control well was not treated with SDS (A).
After one more day of incubation, live cells were photographed under
phase contrast microscopy. Scale bar: 45 mm.
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increase in PAI-2 mRNA, which plateaued at 16 h (Fig 4A). This
plateau was maintained in some cultures until 24 h, but in other
cultures PAI-2 mRNA level had started to decline by this time. A
small effect on PAI-2 antigen was routinely detected at 8 h and a
plateau was reached at 16±24 h (Fig 4B). These experiments were
repeated with keratinocyte cultures initiated from six donors with
similar results.
SDS-mediated enhancement of PAI-2 in cultured
keratinocytes is not due to induction of nonspeci®c cell
lysis SDS is known to exert cytotoxic effects on human
epidermal keratinocytes and cell lines (Eun et al, 1994; Brosin
et al, 1997). To determine if the SDS effect on PAI-2 expression
in vitro was related to direct cytotoxicity, we performed the
following experiments. Examination of SDS-treated cultures by
phase contrast microscopy revealed no effect on keratinocyte
morphology at low concentrations (i.e., 3 mg per ml). With the
addition of 6 mg per ml of SDS, there was a very subtle change, in
that some cells appeared slightly more granular and there were
occasional foci that exhibited a more irregular intercellular adhesion
pattern (Fig 5A, B). At 12.5 mg per ml SDS, the culture overall
had a more refractile appearance, and some of the uppermost cells
became elongated, seemingly connected to each other end-to-end
(Fig 4C). Frankly toxic levels of SDS were reached at
concentrations approaching 25 mg per ml, as evidenced by
detachment of the cells from the culture dish (data not shown).
As a quantitative measure of SDS toxic effects, we assayed the
release of LDH into the culture medium, a well-accepted indicator
of cell leakage and lysis. Minimal LDH release (i.e., 2% of maximal)
was noted in keratinocyte cultures treated with SDS at concentra-
tions of 10 mg per ml (Table I). A small increase in LDH release
was noted at 12.5 mg per ml SDS, with a larger increase at 25 mg
per ml. Similar results of LDH release assays were reported by van
Ruissen et al (1998). Comparison of the LDH data with Figs 3 and
4 reveals that the induction of PAI-2 expression by SDS was
manifest at concentrations that were not toxic; however, the
decrease in PAI-2 expression at SDS concentrations of 12.5 mg per
ml was most likely due to increasing toxicity.
The effect of SDS on PAI-2 is not due to TNF-a Among
the many epidermal effects of barrier disruption is the induction of
a number of cytokines, including TNF-a. Induction of TNF-a
mRNA and/or antigen was reported in human and mouse
epidermis in response to tape-stripping or acetone (Wood et al,
1992; Nickoloff, 1994; Tsai et al, 1994). Furthermore, TNF-a
mRNA was induced in mouse keratinocyte culture in response to
SDS (Lisby et al, 1995). TNF-a has been associated with
in¯ammation and is a well-known inducer of PAI-2 in many cell
types, including keratinocytes (Wang and Jensen, 1998). Given
these ties among PAI-2 and TNF-a and SDS treatment, we
considered whether SDS might lead to the enhancement of PAI-2
indirectly through its induction of TNF-a.
Conditioned media from two cultures and lysates from four
cultures that had been treated with SDS for 0±24 h were assayed for
TNF-a using an ELISA. TNF-a was consistently low in the
lysates. In the absence of SDS, cell-associated TNF-a was just at or
below the limit of detection (23±30 pg TNF-a per mg total lysate
protein). In the presence of SDS, cell-associated TNF-a was
elevated modestly, by approximately 2-fold, in two of the four
cultures assayed; the other two cultures showed no effect of SDS on
TNF-a. TNF-a was not detectable in the conditioned media (limit
of detection was 25 pg per ml), in the presence or absence of SDS,
consistent with the low level of TNF-a previously reported in
conditioned media of normal human keratinocyte cultures (Kock
et al, 1990). In all cultures, we con®rmed by Western blotting that
SDS induced PAI-2. These experiments suggested that TNF-a was
probably not involved in the SDS enhancement of PAI-2 in vitro,
but to address this question in another way we performed the
following experiment.
Keratinocyte cultures were treated with SDS in the presence or
absence of a neutralizing antibody to TNF-a. No effect of this
antibody on the SDS induction of PAI-2 was observed (Fig 6). As
a control, we demonstrated that the anti-TNF-a antibody was able
to prevent the effect of exogenously added TNF-a, thereby
con®rming the neutralizing activity of the antibody (Fig 6).
DISCUSSION
SDS is a well-known inducer of experimental irritant contact
dermatitis (Tupker et al, 1990; Lee and Maibach, 1995). The
cutaneous effects of SDS and other irritants are probably due to
several factors, including barrier disruption with resultant trans-
epidermal water loss (Agner and Serup, 1990; Elias and Feingold,
1994; Elias, 1996); collapse of the epidermal Ca2+ gradient (Elias
and Feingold, 1994); induction of in¯ammation (Willis et al, 1993);
release and/or production of cytokines (Nickoloff, 1994; Wood
et al, 1996); increased proteolytic activity (Denda et al, 1997); and
direct metabolic or cytotoxic effects on the living layers of
epidermis (Willis et al, 1989; Fartasch et al, 1998). The relative
importance of and the interrelationships among these factors are
likely to vary with the dose and duration of SDS exposure, and at
present they are not clearly understood. Further understanding of
the direct and indirect mechanisms by which irritants such as SDS
affect the skin is important for predicting the potential irritant
properties of skin care agents and for designing appropriate screens
of such compounds.
In this study we have used the SDS irritant contact dermatitis
model to study the expression of PAI-2 under perturbed conditions
in normal human skin. Our data demonstrate that PAI-2 mRNA
and antigen are induced by topical application of SDS to human
volunteers. There is a wide variation in the extent of the PAI-2
response in vivo, however, as observed previously for clinical
parameters (Lee and Maibach, 1995; Fartasch et al, 1998). Although
Table I. SDS at low concentrations does not cause cell lysis
SDS concentration (mg per ml) % LDH release (6 SD)
0.0 1.00 6 0.29
3.0 0.73 6 0.20
6.0 2.12 6 0.06
8.0 2.11 6 0.08
10.0 1.53 6 0.08
12.5 4.61 6 0.13
25.0 13.71 6 1.4
Figure 6. SDS enhancement of PAI-2 was not secondary to
induction of TNF-a. Human epidermal keratinocytes were propagated
and maintained under low Ca2+ conditions throughout this experiment
in order to maintain the culture as a monolayer and thus allow free
access of antibody to all cells. When the culture wells were
approximately 35% con¯uent, the medium was changed to MCDB
without BPE. The following day, when the cultures were nearly 70%
con¯uent, half of the wells were preincubated for 2 h with 10 mg per ml
mouse anti-TNF-a inhibitory antibody. SDS (at 4 mg per ml) or
recombinant TNF-a (at 50 ng per ml) was then added to the indicated
wells, and incubation was continued for 24 h. Western blot analysis was
performed on the cell lysates, loading 2 mg total cell protein per lane and
detecting with anti-PAI-2 monoclonal antibody.
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SDS induced compaction of the stratum corneum and a mild
in¯ammatory reaction in all six subjects treated in this study, an
increase in PAI-2 was detected only in the four subjects with the
most marked histologic changes.
Previous studies have shown that topical application of SDS
induces enhanced expression of other molecules, including several
enzymes involved in lipid biosynthesis (Grubauer et al, 1987; Elias,
1996); adhesion molecules, such as integrins and ICAM-1
(Lindberg et al, 1990; von den Driesch et al, 1995); and at least
one other proteolytic enzyme inhibitor, SKALP/ela®n (Boelsma
et al, 1998; van Ruissen et al, 1998). It has been convincingly
demonstrated that these increases in protein expression must occur
by several different mechanisms. For example, many events,
including increases in the enzymes involved in lipid biosynthesis,
are signaled by barrier disruption and the resulting transepidermal
water loss (Grubauer et al, 1987; Elias and Feingold, 1994; Elias,
1996). Increases in cytokines fall into a different category of
responses, however, which are not signaled by transepidermal water
loss but rather may be consequent to cellular damage (Denda et al,
1996). SDS and other irritants also induce epidermal hyperproli-
feration, and the mechanism of this response appears to be
multifaceted. In mouse skin, there is evidence that SDS-induced
proliferation is partially related to transepidermal water loss, but that
other factors are also involved (Denda et al, 1996). A study on SDS-
treated human skin revealed no correlation between the extent of
epidermal proliferation and the increase in transepidermal water
loss, leading the authors to suggest that the proliferative effect is
mediated via direct effects on the keratinocytes, resulting in
synthesis or release of mediators (Welzel et al, 1998).
The idea that SDS may exert some of its cutaneous effects via
direct action on the keratinocyte is intriguing and perhaps
unexpected. When topically applied, however, SDS penetrates
the stratum corneum to the underlying viable keratinocytes and the
stroma (Fullerton et al, 1994; Patil et al, 1995). From one study, in
which 1% SDS was applied to human cadaver skin for 24 h, we
have calculated that approximately 24 mg per ml SDS was present
in the epidermis underlying the application chamber (Fullerton
et al, 1994). In hairless rat skin, after similar treatment, the
epidermal concentration of SDS was approximately 1.8 mg per
ml (Patil et al, 1995). Thus the in vivo concentration of SDS is
estimated to be about three orders of magnitude higher than the
concentrations that we found effective for elicitation of PAI-2 in
keratinocyte culture. These estimates of the concentration of SDS
to which the epidermal keratinocyte may actually be exposed in vivo
are of necessity rather crude, and we do not know what
proportions of SDS were trapped in the stratum corneum versus
penetrated to the living layers. Nonetheless, the estimates argue that
epidermal keratinocytes in vivo may be exposed to a suf®ciently
high concentration of SDS for direct effects, including toxic effects
as well as increases in PAI-2, of the detergent to be manifest.
Few studies to date have examined the direct effects of SDS on
cells in vitro. In a study with human keratinocyte cultures, van
Ruissen et al (1998) used northern blot analysis to show that
mRNAs for SKALP and involucrin were markedly upregulated by
SDS at concentrations similar to what we found effective for PAI-
2; however, keratin 1 mRNA was diminished. In mouse
keratinocyte cultures, SDS was found to increase TNF-a mRNA
(Lisby et al, 1995). We do not know if the differences between our
data and other data with regard to involucrin and TNF-a
expression relate to a difference between protein versus mRNA
expression, or to a small difference in culture conditions; or, in the
case of TNF-a, to a species difference. Nonetheless, in contrast to
others' data at the mRNA level, our immunoblots for involucrin
and TNF-a reveal only small and inconsistent effects of SDS
treatment in vitro. Both of these proteins were elevated in epidermis
upon disruption of the barrier in vivo (Tsai et al, 1994; Le et al,
1996). As shown in Figs 3 and 4, the in vitro effect of SDS on PAI-
2 is consistently manifest at both the mRNA and the protein level.
Thus PAI-2 expression in culture, at least under our culture
conditions, appears more consistent with the in vivo epidermal
response than other in vitro markers.
Van Ruissen et al (1998) have argued that SDS and other anionic
detergents induce a switch from the normal keratinocyte differen-
tiation program to a regenerative maturation pathway characteristic
of a number of physiologic and pathologic states such as wound
healing and psoriasis (Mansbridge and Knapp, 1987). This idea is
supported by observations of SDS-induced increases in SKALP,
involucrin, keratin 6, and keratin 16 as well as a decrease in keratin
1 (Boelsma et al, 1998; Ekanayake-Mudiyanselage et al, 1998; van
Ruissen et al, 1998). It is possible that PAI-2 may be another
component of such a response. There is evidence to suggest that
PAI-2 may be enhanced both in psoriatic epidermis (Lyons-
Giordano et al, 1994) and in keratinocytes involved in re-
epithelialization of a skin defect (Bechtel et al, 1998).
The role of PAI-2 during normal epidermal differentiation or
during regenerative maturation is presently unclear, but it may be
signi®cant that two distinct proteolytic enzyme inhibitors are
associated with epidermal perturbation and repair (PAI-2 and
SKALP) in vivo and in vitro. Proteolytic enzyme inhibitors may
serve to protect the skin against proteinases released or induced
during epidermal disruption and the ensuing repair process. SKALP
is not present in normal epidermis, but it is strongly induced during
in¯ammation; furthermore, SKALP is constitutively present in
other strati®ed squamous epithelia (such as esophagus, oral
epithelia, and vagina) where in®ltrating leukocytes appear to be
physiologic (Schalkwijk et al, 1993; Pfundt et al, 1996). This
distribution and the speci®city of SKALP as an inhibitor of two
leukocyte proteinases (elastase and proteinase 3) strongly suggest
that SKALP functions to regulate secreted leukocyte proteinases
and thus protect epithelia from damage (Schalkwijk et al, 1993;
Pfundt et al, 1996). PAI-2 that is induced during epidermal
perturbation may likewise have a protective role. Barrier disruption
has been shown to lead to plasminogen activation in the epidermis
(Denda et al, 1997). Treatment with tranexamic acid, which blocks
activation of plasminogen at the cell surface (Reinartz et al, 1993),
accelerates barrier restoration, suggesting that the increased
proteinase activity is deleterious to recovery (Denda et al, 1997).
It is possible that PAI-2 is a component of the natural control
mechanisms designed to regulate the potentially harmful effects of
plasminogen activation during repair. One important difference
between PAI-2 and SKALP is that the former, but not the latter, is
also synthesized by epidermal keratinocytes under resting condi-
tions (Schalkwijk et al, 1993; Risse et al, 2000). Hence PAI-2 but
not SKALP may also have constitutive roles related to normal
epidermal differentiation.
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